SCHEMBL815747

SCHEMBL815747

CCCO[CH]c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
LMNA P02545 2/20 0.39
RELA Q04206 1/20 0.39
ALDH1A1 P00352 2/20 0.36
LTA4H P09960 2/20 0.36
HPGD P15428 2/20 0.36
CHRNA7 P36544 3/20 0.36
CYP1A2 P05177 2/20 0.36
MAPT P10636 1/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36
CYP2D6 P10635 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NR1I2 O75469 1/20 0.35
CHRNB4 P30926 2/20 0.35
CHRNA3 P32297 2/20 0.35
CHRNA10 Q9GZZ6 2/20 0.35
CHRNA9 Q9UGM1 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL317685 0.87 LTA4H (0.47) MEN1KMT2ALMNARELAALDH1A1
SCHEMBL814450 0.85 LTA4H (0.47) LMNAALDH1A1LTA4HTP53CYP3A4
SCHEMBL815740 0.84 LTA4H (0.46) LMNAALDH1A1LTA4HTP53NR1I2
SCHEMBL8847319 0.84 LTA4H (0.46) LMNAALDH1A1LTA4HTP53NR1I2
SCHEMBL10857428 0.84 LTA4H (0.46) LMNAALDH1A1LTA4HTP53NR1I2
SCHEMBL41193 0.84 LTA4H (0.46) LMNAALDH1A1LTA4HTP53NR1I2
SCHEMBL1272188 0.84 LTA4H (0.46) LMNAALDH1A1LTA4HTP53NR1I2
SCHEMBL93706 0.81 RELA (0.47) MEN1KMT2ALMNARELAALDH1A1
SCHEMBL8340935 0.81 RELA (0.40) MEN1KMT2ARELAALDH1A1HPGD
SCHEMBL2122339 0.80 MEN1 (0.44) MEN1KMT2ALMNARELAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210087163-A1 PHENOXY THIOPHENE SULFONAMIDES AND OTHER COMPOUNDS FOR USE AS INHIBITORS OF BACTERIAL GLUCURONIDASE NORTH CAROLINA CENTRAL UNIVERSITY (US) 2021-03-25 US claimed
EP-2544535-B1 PHENOXY THIOPHENE SULFONAMIDES AND THEIR USE AS INHIBITORS OF GLUCURONIDASE NORTH CAROLINA CENTRAL UNIV (US) 2017-04-19 EP claimed
US-20160237058-A1 PHENOXY THIOPHENE SULFONAMIDES AND OTHER COMPOUNDS FOR USE AS INHIBITORS OF BACTERIAL GLUCURONIDASE NORTH CAROLINA CENTRAL UNIVERSITY (US) 2016-08-18 US claimed
US-20130345235-A1 PHENOXY THIOPHENE SULFONAMIDES AND THEIR USE AS INHIBITORS OF GLUCURONIDASE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2013-12-26 US claimed
US-20130345196-A1 PHENOXY THIOPHENE SULFONAMIDES AND OTHER COMPOUNDS FOR USE AS INHIBITORS OF BACTERIAL GLUCURONIDASE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2013-12-26 US claimed
EP-2544535-A1 PHENOXY THIOPHENE SULFONAMIDES AND THEIR USE AS INHIBITORS OF GLUCURONIDASE North Carolina Central University (US) 2013-01-16 EP claimed
WO-2011112858-A1 PHENOXY THIOPHENE SULFONAMIDES AND THEIR USE AS INHIBITORS OF GLUCURONIDASE NORTH CAROLINA CENTRAL UNIVERSITY (US) 2011-09-15 WO claimed
WO-2011084503-A1 PHENOXY THIOPHENE SULFONAMIDES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES NORTH CAROLINA CENTRAL UNIVERSITY (US) 2011-07-14 WO claimed
US-7247687-B2 Late transition metal catalysts for olefin polymerization and oligomerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-07-24 US claimed
EP-1521758-B1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEM PATENTS INC (US) 2006-05-24 EP claimed
WO-2004007509-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-01-22 WO claimed
US-5885548-A Multiply substituted DTPA derivatives and their metal complexes, and their metal complexes, pharmaceutical agents that contain these complexes, their use in diagnosis and therapy, as well as process for the production of pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 1999-03-23 US claimed
US-5746995-A DTPA derivatives substituted in a novel way, their metal complexes, and their use in diagnosis and therapy SCHERING AKTIENGESELLSCHAFT (DE) 1998-05-05 US claimed
EP-0794939-A1 NOVEL MULTIPLE-SUBSTITUENT DTPA DERIVATIVES AND METAL COMPLEXES THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPLEXES, THEIR USE IN DIAGNOSIS AND THERAPY, METHODS OF PREPARING THE COMPLEXING AGENTS AND COMPLEXES AND METHODS OF PREPARING THE PHARMACEUTICAL COMPOSITIONS SCHERING AKTIENGESELLSCHAFT (DE) 1997-09-17 EP claimed
EP-0794938-A1 NOVEL SUBSTITUTED DTPA DERIVATIVES, THEIR METAL COMPLEXES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPLEXES AND THEIR USE IN DIAGNOSIS AND THERAPY SCHERING AKTIENGESELLSCHAFT (DE) 1997-09-17 EP claimed
EP-0752622-A1 Acetal polymers useful in photosensitive compositions MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-01-08 EP claimed
US-5534381-A POLYMERS FOR LITHOGRAPHIC PRINTING PLATES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-07-09 US claimed
WO-1996016929-A1 NOVEL MULTIPLE-SUBSTITUENT DTPA DERIVATIVES AND METAL COMPLEXES THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPLEXES, THEIR USE IN DIAGNOSIS AND THERAPY, METHODS OF PREPARING THE COMPLEXING AGENTS AND COMPLEXES AND METHODS OF PREPARING THE PHARMACEUTICAL COMPOSITIONS SCHERING AKTIENGESELLSCHAFT (DE) 1996-06-06 WO claimed
WO-1996016928-A1 NOVEL SUBSTITUTED DTPA DERIVATIVES, THEIR METAL COMPLEXES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPLEXES AND THEIR USE IN DIAGNOSIS AND THERAPY SCHERING AKTIENGESELLSCHAFT (DE) 1996-06-06 WO claimed
US-3940395-A CNS DEPRESSANT AMERICAN HOME PRODUCTS CORPORATION (US) 1976-02-24 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345235-A1 PHENOXY THIOPHENE SULFONAMIDES AND THEIR USE AS INHIBITORS OF GLUCURONIDASE CES2, TOP1, GUSB MEN1 4802/4885KMT2A 2947/4885LMNA 4122/4885
US-20160237058-A1 PHENOXY THIOPHENE SULFONAMIDES AND OTHER COMPOUNDS FOR USE AS INHIBITORS OF BACTERIAL GLUCURONIDASE TOP2A, TOP1, PNP MEN1 4695/4885KMT2A 3816/4885LMNA 1659/4885
US-20130345196-A1 PHENOXY THIOPHENE SULFONAMIDES AND OTHER COMPOUNDS FOR USE AS INHIBITORS OF BACTERIAL GLUCURONIDASE TOP2A, TOP1, TOP2B MEN1 4707/4885KMT2A 3685/4885LMNA 1570/4885
US-20210087163-A1 PHENOXY THIOPHENE SULFONAMIDES AND OTHER COMPOUNDS FOR USE AS INHIBITORS OF BACTERIAL GLUCURONIDASE TOP2A, TOP1, PNP MEN1 4695/4885KMT2A 3816/4885LMNA 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.